DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Department of Defense
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising bio
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Next 90 days
Posted
05/04/2026
Closes
2026-09-30
Eligibility
Eligibility
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Program
Funding area
Science and Technology and other Research and Development - ST
Opportunity #
HT942526ALSRPCOBA
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov